For det primære endepunkt, triglycerider, de sekundære endepunkter, LDL- kolesterol, apo B, HDL- kolesterol, non- HDL- kolesterol og VLDL- kolesterol var trend- testene signifikante med hensyn til respons i samtlige behandlingsgrupper med placebo, simvastatin 20, simvastatin 40 og simvastatin 80 mg.
For the primary endpoint, triglycerides, the secondary endpoints, LDL cholesterol, apo B, HDL cholesterol, non-HDL cholesterol, and VLDL cholesterol, the trends tests were significant in the response across placebo, simvastatin 20, simvastatin 40, and simvastatin 80 mg.